| P2093 | author name string | G. A. Pietersz | |
| | I. F. McKenzie | |
| | A. J. Rowland | |
| P2860 | cites work | A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 |
| | Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion | Q33352919 |
| | Phase I study of 4-demethoxydaunorubicin | Q33479733 |
| | Antibody conjugates for the treatment of cancer | Q35595959 |
| | Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. | Q37404033 |
| | An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use | Q38332089 |
| | Immunotoxins: a clinical review of their use in the treatment of malignancies | Q38725006 |
| | Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose | Q39218339 |
| | Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations | Q39548934 |
| | The toxicity of chemically deglycosylated ricin A-chain in mice | Q40737523 |
| | Phase I immunotoxin trial in patients with B-cell lymphoma | Q40746210 |
| | The surface antigens of human B lymphocytes | Q41334006 |
| | Tumor localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line (LIM1899). | Q41722400 |
| | Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing | Q43786477 |
| | Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma | Q45252963 |
| | CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA. | Q52828546 |
| | Inhibition, by vinca alkaloids and colchicine, of antigenic modulation induced by anti-CD19 monoclonal antibodies. | Q54391719 |
| | Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody | Q67685133 |
| | Preparation and characterization of a chimeric CD 19 monoclonal antibody | Q67714030 |
| | Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors | Q67720709 |
| | Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins | Q68090182 |
| | Production of monoclonal antibodies to serum antigens in colorectal carcinoma | Q68140254 |
| | Antitumor activity of idarubicin-monoclonal antibody conjugates in a disseminated thymic lymphoma model | Q68183386 |
| | Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates | Q68519005 |
| | Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies | Q68720076 |
| | Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas | Q68812167 |
| | Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody | Q68812235 |
| | Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin | Q68973456 |
| | Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy | Q69023454 |
| | Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody | Q69520763 |
| | Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies | Q69522036 |
| | Treatment of two patients with B cell lymphoma with monoclonal anti-idiotype antibodies | Q69868005 |
| | A clinical trial of anti-idiotype therapy for B cell malignancy | Q69891840 |
| | Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution | Q70078986 |
| | Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses | Q70966489 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 195-202 | |
| P577 | publication date | 1993-08-01 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates | |
| P478 | volume | 37 | |